CALCIUM ACETATE | N022581 | FRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Beckloff Associates - Citizen Petition FDA-2006-P-0327 · 6 docket documents Beckloff Associates filed this citizen petition on behalf of a client requesting that the FDA determine whether PhosLo (calcium acetate) Tablets and Capsules, both containing 169 mg calcium equivalent and approved under NDA Nos. 019-976 and 021-160 respectively, were withdrawn from sale for safety o | 505(q) | 2009-01-15 | Open | — |
Citizen Petition from Lachman Consultant Services, Inc. FDA-2006-P-0445 · 6 docket documents Lachman Consultant Services, Inc., on behalf of a client, filed a citizen petition requesting that the FDA determine whether Phoslo (calcium acetate) Tablets, equivalent to 169 mg calcium, approved under NDA 19-976, were voluntarily withdrawn from sale for safety or effectiveness reasons, as the inn | 505(q) | 2008-06-24 | Open | Lachman Consultant Services, Inc. |
Citizen Petition from Lachman Consultant Services, Inc. FDA-2006-P-0446 · 4 docket documents Lachman Consultant Services, Inc. filed this petition on behalf of an unnamed client requesting that the FDA determine whether Phoslo (calcium acetate) Capsules equivalent to 169 mg calcium, approved under NDA 21-160, was voluntarily withdrawn from sale for reasons of safety or effectiveness, as the | 505(q) | 2008-06-24 | Withdrawn | Lachman Consultant Services, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.